Encouraging survival observed with Opdivo (nivolumab) plus Yervoy (ipilimumab)
Bristol-Myers Squibb announced updated findings from the Phase 1b trial, CheckMate -012, in chemotherapy-naïve advanced non-small cell lung cancer patients evaluating Opdivo monotherapy, or in combination with Yervoy, at different doses and schedules. December 05, 2016